Cargando…

Intestinal Barrier in Human Health and Disease

The intestinal mucosa provides a selective permeable barrier for nutrient absorption and protection from external factors. It consists of epithelial cells, immune cells and their secretions. The gut microbiota participates in regulating the integrity and function of the intestinal barrier in a homeo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Tommaso, Natalia, Gasbarrini, Antonio, Ponziani, Francesca Romana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657205/ https://www.ncbi.nlm.nih.gov/pubmed/34886561 http://dx.doi.org/10.3390/ijerph182312836

Ejemplares similares

The Gut–Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases
por: Di Tommaso, Natalia, et al.
Publicado: (2023)

Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship
por: Manilla, Vittoria, et al.
Publicado: (2023)

Role of Akkermansia in Human Diseases: From Causation to Therapeutic Properties
por: Pellegrino, Antonio, et al.
Publicado: (2023)

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
por: Pallozzi, Maria, et al.
Publicado: (2022)

Type 2 Diabetes Mellitus and Liver Disease: Across the Gut–Liver Axis from Fibrosis to Cancer
por: Manilla, Vittoria, et al.
Publicado: (2023)

Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation
por: Nicoletti, Alberto, et al.
Publicado: (2019)

Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut–Liver Axis
por: Cerreto, Maria, et al.
Publicado: (2021)

Viral Cirrhosis: an Overview of Haemostatic Alterations and Clinical Consequences
por: Ponziani, Francesca Romana, et al.
Publicado: (2009)

Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis
por: Giuli, Lucia, et al.
Publicado: (2023)

Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows
por: Costante, Federico, et al.
Publicado: (2022)

Gut Microbiota and Infectious Complications in Advanced Chronic Liver Disease: Focus on Spontaneous Bacterial Peritonitis
por: Maccauro, Valeria, et al.
Publicado: (2023)

Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives
por: Paratore, Mattia, et al.
Publicado: (2021)

NAFLD or comorbidities, that is the question
por: Ponziani, Francesca Romana, et al.
Publicado: (2020)

Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment
por: Stella, Leonardo, et al.
Publicado: (2022)

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies
por: Maestri, Marta, et al.
Publicado: (2023)

Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2019)

Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship
por: Nesci, Antonio, et al.
Publicado: (2023)

Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers
por: Cerrito, Lucia, et al.
Publicado: (2019)

Effect of liver transplantation on intestinal permeability and correlation with infection episodes
por: Ponziani, Francesca Romana, et al.
Publicado: (2020)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection
por: Costante, Federico, et al.
Publicado: (2023)

Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications
por: Airola, Carlo, et al.
Publicado: (2023)

Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases
por: Rinninella, Emanuele, et al.
Publicado: (2020)

Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders
por: Di Vincenzo, Federica, et al.
Publicado: (2023)

The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
por: Cerreto, Maria, et al.
Publicado: (2023)

Factors Influencing Microbiota in Modulating Vaccine Immune Response: A Long Way to Go
por: Ponziani, Francesca Romana, et al.
Publicado: (2023)

COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms
por: Settanni, Carlo Romano, et al.
Publicado: (2021)

Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection
por: Ponziani, Francesca Romana, et al.
Publicado: (2021)

Human Intestinal Barrier Function in Health and Disease
por: König, Julia, et al.
Publicado: (2016)

Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients
por: De Maio, Flavio, et al.
Publicado: (2020)

Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients
por: Faccia, Mariella, et al.
Publicado: (2022)

Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
por: Airola, Carlo, et al.
Publicado: (2023)

SIRT in 2025
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients
por: Del Zompo, Fabio, et al.
Publicado: (2021)

Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges
por: Rinninella, Emanuele, et al.
Publicado: (2020)

Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease
por: Giuli, Lucia, et al.
Publicado: (2023)

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends
por: Posa, Alessandro, et al.
Publicado: (2023)

Low ADAMTS-13/VWF ratio and altered gut–liver axis predict complications of advanced chronic liver disease: a pilot study
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l1m52qjj3hl6v7vct3aamlv45t